ERBB2 and neoplasm: Although primary metastatic breast cancer had a significantly lower HER2-low discordance rate than secondary metastatic breast cancer, it has been observed that relevant HER2 discordance rates are observed between different metastatic sites and molecular subtypes, therefore highlighting the importance of evaluating potentially therapy-relevant HER2-low discordance rates between a primary tumor and corresponding distant metastases [22].